Logo image of IMV

IMV INC (IMV) Stock Fundamental Analysis

NASDAQ:IMV - Nasdaq - CA44974L3011 - Common Stock - Currency: USD

0.8225  -0.02 (-2.55%)

After market: 0.8 -0.02 (-2.74%)

Fundamental Rating

2

IMV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. Both the profitability and financial health of IMV have multiple concerns. IMV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMV has reported negative net income.
IMV had a negative operating cash flow in the past year.
IMV had negative earnings in each of the past 5 years.
IMV had a negative operating cash flow in each of the past 5 years.
IMV Yearly Net Income VS EBIT VS OCF VS FCFIMV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

IMV has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMV Yearly ROA, ROE, ROICIMV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -5K -10K

1.3 Margins

IMV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMV Yearly Profit, Operating, Gross MarginsIMV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -5K -10K -15K -20K

More info and screens

2

2. Health

2.1 Basic Checks

IMV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMV has been increased compared to 1 year ago.
Compared to 1 year ago, IMV has a worse debt to assets ratio.
IMV Yearly Shares OutstandingIMV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
IMV Yearly Total Debt VS Total AssetsIMV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -12.68, we must say that IMV is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -12.68, IMV is not doing good in the industry: 82.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.68
ROIC/WACCN/A
WACC6.97%
IMV Yearly LT Debt VS Equity VS FCFIMV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

2.3 Liquidity

A Current Ratio of 2.93 indicates that IMV has no problem at all paying its short term obligations.
With a Current ratio value of 2.93, IMV is not doing good in the industry: 71.88% of the companies in the same industry are doing better.
IMV has a Quick Ratio of 2.93. This indicates that IMV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.93, IMV is doing worse than 70.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.93
IMV Yearly Current Assets VS Current LiabilitesIMV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.44% over the past year.
IMV shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.21%.
IMV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.12% yearly.
EPS 1Y (TTM)4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.29%
Revenue 1Y (TTM)37.21%
Revenue growth 3Y-8.54%
Revenue growth 5Y14.12%
Sales Q2Q%337.14%

3.2 Future

The Earnings Per Share is expected to grow by 15.36% on average over the next years. This is quite good.
The Revenue is expected to grow by 162.00% on average over the next years. This is a very strong growth
EPS Next Y20.34%
EPS Next 2Y22.41%
EPS Next 3Y17.34%
EPS Next 5Y15.36%
Revenue Next Year-80.66%
Revenue Next 2Y59.28%
Revenue Next 3Y71.75%
Revenue Next 5Y162%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IMV Yearly Revenue VS EstimatesIMV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
IMV Yearly EPS VS EstimatesIMV Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMV Price Earnings VS Forward Price EarningsIMV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMV Per share dataIMV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

IMV's earnings are expected to grow with 17.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.41%
EPS Next 3Y17.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMV INC

NASDAQ:IMV (4/28/2023, 8:22:14 PM)

After market: 0.8 -0.02 (-2.74%)

0.8225

-0.02 (-2.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16 2023-03-16/bmo
Earnings (Next)05-11 2023-05-11/bmo
Inst Owners0.01%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.63M
Analysts80
Price Target21.8 (2550.46%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.77%
Min EPS beat(2)18.66%
Max EPS beat(2)24.89%
EPS beat(4)4
Avg EPS beat(4)17.9%
Min EPS beat(4)11.99%
Max EPS beat(4)24.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)362.62%
Min Revenue beat(2)302.87%
Max Revenue beat(2)422.36%
Revenue beat(4)3
Avg Revenue beat(4)202.15%
Min Revenue beat(4)-14.65%
Max Revenue beat(4)422.36%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.67%
PT rev (3m)-7.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.5%
EPS NY rev (1m)-12.6%
EPS NY rev (3m)-782.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)-84.75%
Revenue NY rev (3m)-88.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.21
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.59
EYN/A
EPS(NY)-3.66
Fwd EYN/A
FCF(TTM)-2.94
FCFYN/A
OCF(TTM)-2.85
OCFYN/A
SpS0.03
BVpS-0.56
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 107.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.93
Quick Ratio 2.93
Altman-Z -12.68
F-Score2
WACC6.97%
ROIC/WACCN/A
Cap/Depr(3y)151.06%
Cap/Depr(5y)243.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.29%
EPS Next Y20.34%
EPS Next 2Y22.41%
EPS Next 3Y17.34%
EPS Next 5Y15.36%
Revenue 1Y (TTM)37.21%
Revenue growth 3Y-8.54%
Revenue growth 5Y14.12%
Sales Q2Q%337.14%
Revenue Next Year-80.66%
Revenue Next 2Y59.28%
Revenue Next 3Y71.75%
Revenue Next 5Y162%
EBIT growth 1Y-8.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.84%
EBIT Next 3Y-3.45%
EBIT Next 5Y16.26%
FCF growth 1Y-3.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.22%
OCF growth 3YN/A
OCF growth 5YN/A